Biotech · Private company · North Andover, MA, US

Embiosys Inc.

Track this companyFree. Adds Embiosys Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards4

CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast CancerFiscal year 2026 · $870.5KNIH RePORTER 5R44CA310518-02 · fetched Nov 12, 2026
CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast CancerFiscal year 2025 · $1.4MNIH RePORTER 1R44CA310518-01 · fetched Nov 12, 2026
DEVELOPMENT OF A WEARABLE, NON-INVASIVE, TREATMENT DEVICE FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)Fiscal year 2025 · $188.9KNIH RePORTER 5R43CA287836-02 · fetched Nov 12, 2026
DEVELOPMENT OF A WEARABLE, NON-INVASIVE, TREATMENT DEVICE FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)Fiscal year 2024 · $211.1KNIH RePORTER 1R43CA287836-01 · fetched Nov 12, 2026